Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major

Haematologica

Volumn 98, Issue 4, 2013, Pages 555-559

  Forni, Gian Luca ^a   Podestà, Marina ^b   Musso, Marco ^a   Piaggio, Giovanna ^c   Musallam, Khaled M ^d   Balocco, Manuela ^a   Pozzi, Sarah ^c   Rosa, Alessandra ^a   Frassoni, Francesco ^b  

^a GALLIERA HOSPITAL   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD SAMPLING; BURST FORMING UNIT E; CELL ISOLATION; CHELATION THERAPY; CLONOGENIC ASSAY; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; SPLENECTOMY; THALASSEMIA MAJOR;

ADULT; BENZOATES; BETA-THALASSEMIA; BLOOD CELL COUNT; CHELATION THERAPY; COLONY-FORMING UNITS ASSAY; CROSS-SECTIONAL STUDIES; DEFEROXAMINE; ERYTHROID PRECURSOR CELLS; FEMALE; FERRITINS; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; IRON CHELATING AGENTS; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; MYELOID PROGENITOR CELLS; PYRIDONES; SPLENECTOMY; TRIAZOLES; YOUNG ADULT;

EID: 84875644850     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.076240     Document Type: Article

References (33)

1. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-46.
2. Cazzola M, Finch CA. Evaluation of erythroid marrow function in anemic patients. Haematologica. 1987;72(3):195-200.
3. Cazzola M, Pootrakul P, Huebers HA, Eng M, Eschbach J, Finch CA. Erythroid marrow function in anemic patients. Blood. 1987; 69(1):296-301.
4. Cazzola M, De Stefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C, et al. Relationship between transfusion regimen and suppression of erythropoiesis in betathalassaemia major. Br J Haematol. 1995; 89(3):473-8.
5. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479-88.
6. Ginzburg Y, Rivella S. beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011;118(16):4321-30.
7. Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, Ferrari G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood. 2012;119(21):5021-9.
8. Li H, Rybicki AC, Suzuka SM, von Bonsdorff L, Breuer W, Hall CB, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010;16 (2):177-82.
9. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest. 2010;120(12):4466-77.
10. Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, et al. Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. Haematologica. 2012;97(9):1364-71.
11. Guariglia R, Martorelli MC, Villani O, Pietrantuono G, Mansueto G, D'Auria F, et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res. 2011;35(5):566-70.
12. Oliva EN, Ronco F, Marino A, Alati C, Pratico G, Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010;50(7):1568-70.
13. Taher AT, Musallam KM, Koussa S, Inati A. Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy. Ann Hematol. 2009;88(12):1263-4.
14. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol. 2007;78(6):540-2.
15. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94 (2):288-99.
16. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120(2):70-4.
17. Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122(2):305-10.
18. Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the clinical management of thalassemia. 2nd rev ed. Nicosia, Cyprus: Thalassaemia International Federation, 2009.
19. Chin-Yee I, Keeney M, Anderson L, Nayar R, Sutherland DR. Current status of CD341 cell analysis by flow cytometry: the ISHAGE guidelines. Clin Immunol Newslett. 1997;17:21-9.
20. Sutherland RM, Boyle W. Different activation signals detected by fixation of stimulator cells. Transplant Proc. 1989;21(1 Pt 1):178-9.
21. Yannaki E, Papayannopoulou T, Jonlin E, Zervou F, Karponi G, Xagorari A, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 2012;20(1):230-8.
22. Chen JS, Lin KH, Tsao CJ. Peripheral blood hematopoietic progenitor cells in beta-thalassemia major. Int J Cell Cloning. 1992; 10(6):338-43.
23. Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood. 1993;81(4):1067-76.
24. Nisli G, Kavakli K, Aydinok Y, Oztop S, Cetingul N. Serum erythropoietin levels in patients with beta thalassemia major and intermedia. Pediatr Hematol Oncol. 1997;14 (2):161-7.
25. Kutukculer N, Vergin C, Cetingul N, Kavakli K, Caglayan S, Oztop S, et al. Plasma interleukin-3 (IL-3) and IL-7 concentrations in children with homozygous beta-thalassemia. J Trop Pediatr. 1997;43(6):366-7.
26. Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am J Hematol. 2002;70(2):100-6.
27. Wiener E, Wanachiwanawin W, Chinprasertsuk S, Siripanyaphinyo U, Mawas F, Fucharoen S, et al. Increased serum levels of macrophage colony-stimulating factor (M-CSF) in alpha-and beta-thalassaemia syndromes: correlation with anaemia and monocyte activation. Eur J Haematol. 1996;57(5):364-9.
28. Chuncharunee S, Archararit N, Hathirat P, Udomsubpayakul U, Atichartakarn V. Levels of serum interleukin-6 and tumor necrosis factor in postsplenectomized thalassemic patients. J Med Assoc Thai. 1997;80 (Suppl 1):S86-91.
29. Noga SJ. Graft engineering. Semin Oncol. 2000;27(2 Suppl 5):15-21.
30. Fontao-Wendel R, Lazar A, Melges S, Altobeli C, Wendel S. The absolute number of circulating CD34+ cells as the best predictor of peripheral hematopoietic stem cell yield. J Hematother. 1999;8(3):255-62.
31. Messa E, Carturan S, Maffe C, Pautasso M, Bracco E, Roetto A, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95(8):1308-16.
32. Meytes D, Ortega JA, Ma A, Wald BR, Shore NA, Dukes PP. The relationship between human spleen and blood erythroid burstforming units (BFU-E). Br J Haematol. 1983;55(2):347-56.
33. Issaragrisil S, Tang-naitrisorana Y, Piankijagum A, Fucharoen S, Wasi P. Study of hematopoietic progenitors in patients with thalassemia: the effect of splenectomy. Birth Defects Orig Artic Ser. 1988;23(5B): 323-9.